<![CDATA[Copenhagen, Denmark; July 26, 2011 – Genmab A/S (OMX: GEN) announced today that the Arzerra® (ofatumumab) net sales during the second quarter of 2011 were GBP 10.5 million (approximately DKK 88.6 mill]]>Copenhagen, Denmark; July 26, 2011 – Genmab A/S (OMX: GEN) announced today that the Arzerra® (ofatumumab) net sales during the second quarter of 2011 were GBP 10.5 million (approximately DKK 88.6 million). This figure consists of net sales in the U.S. of GBP 7.4 million (approximately DKK 62.4 million) and in the rest of the world GBP 3.1 million (approximately DKK 26.2 million). Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 17.7 million.

Welcome to Genmab

favicon

(www.genmab.com)

]]>https://dev.proinvestor.com/forum/topic/448384/copenhagen-denmark-july-26-2011-genmab-as-omx-gen-announced-today-that-the-arzerra-ofatumumab-net-sales-during-the-second-quarter-of-2011-were-gbp-105-million-approximately-dkk-886-millRSS for NodeSat, 20 Jun 2026 11:27:51 GMTTue, 26 Jul 2011 09:36:30 GMT60